HD-OPM Archive
Hashtags

#cetpinhibitor

12 posts

HDL and ApoA-I raising therapies repeatedly failed, so HDL is probably not directly causal

Mar 11, 2024 · Louis Nervegna ♥ 6 · 💬 9 ↩ 22 LDL, ApoB & lipid panel

Louis reviews why HDL or ApoA-I is probably not causal for heart disease. CETP inhibitor trials failed (ILLUMINATE with torcetrapib was stopped for harm; dal-OUTCOMES with dalcetrapib and ACCELERATE with evacetrapib showed no benefit), as did fibrate and niacin trials and CSL112 infusions, and Mendelian randomization agrees. He proposes HDL and ApoA-I mainly act as a proxy for insulin sensitivity, which is the real causal factor.

Obicetrapib gets first approval worldwide in the EU, lowering LDL up to 40-50%

Sep 21, 2026 · Louis Nervegna ♥ 18 · 💬 5 PCSK9, ezetimibe & newer drugs

The European Commission approved obicetrapib, a low-dose oral CETP inhibitor, on 21 September 2026 in two versions: obicetrapib 10 mg alone and combined with ezetimibe 10 mg. Phase 3 trials reported LDL-C reductions of about 40% alone and about 50% with ezetimibe versus placebo. The poster says the drug has shown promise for both cardiovascular disease and Alzheimer's.